BioPorto Receives FDA 510(k) Clearance for NGAL Test in the United States First Test to Aid in Assessing AKI Risk for Patients Aged 3 Months Through 21 Years -December 07, 2023 at 04:23 pm EST
December 7, 2023 Announcement no. 20 BioPorto Receives FDA 510 Clearance for NGAL Test in the United StatesFirst Test to Aid in Assessing AKI Risk for Patients Aged 3 Months Through 21 Years ...